Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures
Nancy Wareing(Emory University), Shervin Assassi(University of Houston), Keith M. Sullivan(Duke Medical Center), Daniel E. Furst(University of California, Los Angeles), Richard A. Nash(Colorado Blood Cancer Institute), Leslie J. Crofford(Vanderbilt University Medical Center), Marka A. Lyons(The University of Texas Health Science Center), Xuan Wang(Anhui University of Finance and Economics), Peter A. McSweeney(Mesoblast (United States)), Lynette Keyes‐Elstein(Rho (United States)), Beverly Welch(National Institute of Allergy and Infectious Diseases), Ashley Pinckney(National Institute of Allergy and Infectious Diseases), Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), Maureen D. Mayes(The University of Texas Health Science Center)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k